What is Corvus's gross profit margin?

What were the key takeaways from Corvus's earnings call?

Did Corvus beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Corvus year over year?

What factors drove the changes in Corvus's revenue and profit?

What is the market's earnings forecast for Corvus next quarter?

What is Corvus's latest dividend and current dividend yield?

What does Corvus do and what are its main business segments?

- **Financial Strength:** $246M cash post-January offering, extending runway to Q2 2028.
- **Socolitinib AD Breakthrough:** 72% EASI-75 response, no rebound, and broad applicability in resistant patients.
- **Pipeline Expansion:** HS and asthma trials planned; ITK inhibition shows potential for multiple inflammatory diseases.
- **PTCL Momentum:** Phase III trial progressing with interim analysis expected in 2026.

**【CFO Financial Commentary】**
- Q4 2025 R&D expenses: $9.9M (vs. $6M in 2024), driven by socolitinib trials and manufacturing costs.
- Net loss: $12.3M (Q4 2025) vs. $12.1M (Q4 2024), with $0.7M non-cash loss from equity investments.
- Cash as of Dec 31, 2025: $56.8M, plus $189M from January public offering, extending cash runway to Q2 2028.

**【CEO Business Update】**
- **Socolitinib Phase I AD Trial (Cohort 4):**
  - 72% EASI-75 response vs. 25% placebo; 33% achieved IGA 0/1.
  - No rebound observed; durability maintained for 90 days post-treatment.
  - Safe profile: no new safety signals, similar AEs to placebo.
- **Phase II AD Trial Initiated:**
  - 200Mg BID, 400Mg QD, and placebo arms; 12-week treatment + 90-day follow-up.
  - Enrollment of 200 patients with moderate-to-severe AD.
- **Pipeline Expansion:**
  - Hidradenitis suppurativa (HS) Phase II trial planned for 2026; targeting IL-17 pathway.
  - Asthma trial design under development, focusing on 3-month treatment period.
- **PTCL Phase III Trial:**
  - Ongoing with interim analysis expected later in 2026; 200Mg BID dose shows PFS of 6.2 months in Phase IIb.

**【Q&A Highlights】**
- **China AD Trial Update:**
  - Angel Pharmaceuticals' Phase Ib/II trial enrolling 48 patients; 12-week data expected late 2026.
- **AD Trial Benchmarking:**
  - Targeting efficacy superior to biologics (e.g., dupilumab); 72% EASI-75 vs. ~25% in prior therapies.
- **Asthma Strategy:**
  - Leveraging socolitinib's broad cytokine inhibition; animal models show strong efficacy.
- **ALPS Trial Progress:**
  - 3 patients on therapy >1 year; exploring expansion into pediatric population.


Corvus Pharmaceuticals, Inc.(CRVS)-20260313-2025 Q4 Earnings call transcript

- **Financial Stability**: $65.7M cash runway supports operations into 2026; R&D expenses up 63% due to soquelitinib trials.
- **Atopic Dermatitis Milestones**: Cohort 4 data (Jan 2026) and Phase II trial (Q1 2026) targeting JAK/Dupixent-refractory patients.
- **Oncology Momentum**: ASH presentation highlights soquelitinib's >12-month PFS in PTCL; Phase III interim data expected late 2026.
- **Strategic Growth**: Exploring asthma, HS, and other I&amp;I indications; new board member to guide commercialization.

**【CFO Financial Commentary】**
- Q3 2025 R&D expenses: $8.5M (vs. $5.2M in 2024), driven by soquelitinib clinical trials and manufacturing costs.
- Net loss: $10.2M (vs. $40.2M in 2024), with $300K non-cash loss from China partner.
- Cash reserves: $65.7M as of Q3 2025, sufficient for operations into Q4 2026.

**【CEO Business Update】**
- **Atopic Dermatitis Progress**: 
  - Phase I Cohort 4 (24 patients) completed enrollment; 8-week data to be reported in January 2026.
  - Cohort 3 showed 64.8% EASI reduction vs. 34% placebo; 50% of patients achieved EASI 75.
  - Phase II trial (200 patients) to begin Q1 2026, targeting JAK/Dupixent-refractory patients.
- **Oncology Update**: 
  - ASH 2025 oral presentation highlights soquelitinib's durability in relapsed PTCL (median PFS >12 months).
  - Phase III PTCL trial enrolling; interim data expected late 2026.
- **Strategic Expansion**: 
  - Exploring asthma, hidradenitis suppurativa, and other I&amp;I indications.
  - New board member, David Moore (Novo Nordisk), to advise on commercial strategy.

**【Q&A Highlights】**
- **Cohort 4 Expectations**: Seeking consistency with Cohort 3 data and potential improvement with extended dosing.
- **Phase II Design**: 12-week treatment duration; no subgroup powering for JAK/Dupixent failure.
- **Biomarker Strategy**: Focusing on single-cell RNA sequencing of blood for novel biomarkers.
- **Partnership Potential**: Open to licensing deals but prioritizing internal development of soquelitinib.
- **Oncology Outlook**: PTCL trial control arm expected median PFS of 2-3 months, vs. soquelitinib's >12-month PFS in Phase I.

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript

- **Financial Strength**: $74.4M cash (including $35.7M from warrant exercises), funding operations into Q4 2026.
- **Soquelitinib Success**: Cohort 3 achieves 64.8% EASI reduction, Phase II trial set to begin Q4 2025.
- **Strategic Expansion**: Exploring hidradenitis suppurativa and asthma for soquelitinib, with next-gen ITK inhibitor in development.
- **Clinical Momentum**: Phase III PTCL trial on track for 2026 data, ciforadenant renal cancer results due in October.

**【CFO Financial Commentary】**
- Q2 2025 R&D expenses: $7.9M (vs. $4.1M in Q2 2024), driven by soquelitinib clinical trials and manufacturing costs.
- Net loss: $8M (including $400K noncash loss from China partner) vs. $4.3M in Q2 2024.
- Cash reserves: $74.4M (vs. $52M at year-end 2024), with $35.7M from warrant exercises.
- Cash runway: Expected to fund operations into Q4 2026.

**【CEO Clinical Update】**
- **Soquelitinib Phase I Results**: Cohort 3 (200mg BID) achieved 64.8% EASI reduction at 4 weeks, vs. 54.6% in Cohorts 1/2 and 34.4% in placebo. 50% of Cohort 3 patients reached EASI-75, with no safety issues.
- **Extension Cohort 4**: 24 patients (12 active/12 placebo) to evaluate 8-week treatment duration, data expected Q4 2025.
- **Phase II Trial Design**: 200-patient, 12-week trial with 4 arms (200mg QD, 200mg BID, 400mg QD, placebo). Primary endpoint: EASI change; secondary: EASI-75, IGA 0/1, PP-NRS reduction.
- **PTCL Progress**: Phase III trial enrolling as planned, targeting late 2026 interim data.
- **Ciforadenant Update**: Phase II renal cell cancer data to be presented at ESMO in October.

**【Q&A Highlights】**
- **Future Indications**: Potential expansion into hidradenitis suppurativa (dermatology) and asthma (pulmonary), leveraging ITK's role in innate lymphoid cells.
- **Trial Design Rationale**: FDA-standard 200-patient Phase II with 50/50 randomization to assess dose-response and safety.
- **Next-Gen ITK Inhibitor**: Development underway, targeting distinct ITK-mediated pathways for unmet needs in inflammation and oncology.

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

- **Financial Strength**: $31.3M from warrant exercises extends cash runway to Q4 2026.
- **AD Trial Success**: Cohort 3 (200mg BID) achieves 63% EASI 75 vs. 29% in lower doses; no safety issues.
- **Pipeline Momentum**: Phase 3 PTCL trial on track; Phase 2 ALPS trial begins in 2025.
- **Dosing Insights**: 200mg BID shows faster efficacy; QD dosing to be tested in Phase 2.
- **Strategic Focus**: Self-funded development with potential for combination therapies.

**【CFO Financial Highlights】**
- Q1 2025 R&D expenses: $7.5M (vs. $4.1M in Q1 2024), driven by soquelitinib clinical trials and manufacturing costs.
- Net income: $15.2M (including $25.1M warrant liability gain) vs. net loss of $5.7M in Q1 2024.
- Cash as of March 31, 2025: $44.2M (plus $31.3M from warrant exercises in May 2025).
- Cash runway extended to Q4 2026, supporting Phase 1/2 AD trials and lymphoma Phase 3.

**【CEO Clinical Trial Update】**
- **Soquelitinib Phase 1 AD Data Highlights**: 
  - Cohort 3 (200mg BID): 63% EASI 75 vs. 29% in Cohorts 1/2; 13% EASI 90 vs. 4% in earlier cohorts.
  - No safety concerns; nausea (Grade 1) only adverse event.
  - Extension cohort (24 patients, 200mg BID x8 weeks) to evaluate longer-term efficacy.
- **Lymphoma Pipeline**: Phase 3 PTCL trial ongoing; Phase 2 ALPS trial initiated.
- **Warrant Exercise Impact**: $31.3M from warrant exercises supports 2025-2026 trial timelines.

**【Q&A Key Takeaways】**
- **Dose Efficacy**: 200mg BID (Cohort 3) shows faster, deeper responses vs. 200mg QD (Cohorts 1/2).
- **Placebo Effect**: Similar to industry standards; no rebound events observed.
- **Future Trials**: Phase 2 AD trial design to include 200mg BID and potential QD dosing.
- **Partnership Strategy**: No immediate plans for collaborations; focused on internal development.
- **Combination Potential**: Exploring soquelitinib with IL-4/13 inhibitors, though prioritizing monotherapy.


Corvus Pharmaceuticals (CRVS)-8 May 25-2025 Q1 Earnings call transcript

- **Financial resilience**: $52 million cash, potential $41 million from warrant exercises, runway to Q1 2026.
- **AD progress**: 37% EASI 75 in Phase I, Cohort 3 data due May 2025; Cohort 4 decision pending.
- **Lymphoma momentum**: 39% ORR in PTCL Phase I vs. ~20% for SOC, Phase III enrollment advancing.
- **New frontiers**: ALPS trial for 2,500 rare disease patients; RCC Phase II to test ITK in solid tumors.

**【CFO Financial Overview】**
- Q4 2024 R&D expenses: $6 million (vs. $4 million in 2023), driven by soquelitinib clinical trials.
- Full year 2024 net loss: $63.3 million, including $3.2 million noncash loss from China partner and $33.4 million warrant liability adjustment.
- Cash balance as of Dec 31, 2024: $52 million, with $41 million potential from warrant exercises, providing runway to Q1 2026.

**【CEO Business Update】**
- **Soquelitinib in T-cell lymphoma**: 39% ORR (26% CR) in Phase I, with Phase III enrollment ongoing vs. belinostat/pralatrexate.
- **Atopic dermatitis (AD) Phase I**: 37% EASI 75 and 26% IGA 0/1 in active vs. 0% placebo; Cohort 3 (400mg BID) nearing completion for May 2025 data.
- **ALPS Phase II**: 30-patient trial with 200/400mg BID, targeting lymphoproliferation and cytopenias.
- **Solid tumor plans**: RCC Phase II to start Q3 2025, leveraging ITK's role in immune modulation.

**【Key Q&A Highlights】**
- **AD Cohort 4**: Pending Cohort 3 data, may proceed with 400mg QD if efficacy supports.
- **ALPS market size**: ~2,500 U.S. patients; no subset identified for differential response.
- **Oncology vs. immunology strategy**: Separate pipelines for oncology (ITK-selective) and autoimmune (broader ITK inhibition).

Corvus Pharmaceuticals (CRVS)-25 Mar 25-2024 Q4 Earnings call transcript

Corvus Pharmaceuticals (CRVS)-12 Nov 24-2024 Q3 Earnings call transcript

Corvus Pharmaceuticals (CRVS)-6 Aug 24-2024 Q2 Earnings call transcript

Corvus Pharmaceuticals (CRVS)-6 May 24-2024 Q1 Earnings call transcript

Corvus Pharmaceuticals (CRVS)-19 Mar 24-2023 Q4 Earnings call transcript

- **Financial Stability**: $32.2M cash balance with 2024 runway; R&D expenses down 62% YoY.
- **Key Trial Milestone**: Phase III PTCL trial set to start Q2 2024 with U.S.-led sites.
- **Breakthrough Immune Data**: ITK inhibition blocks 3+ cytokines in preclinical models; Th1 sparing mechanism unique vs biologics.
- **Upcoming Catalysts**: ASH 2023 data (PTCL durability, Th1/Th2 balance), Q1 2024 RCC trial start, and 2024 interim ciforadenant data.
- **Partnership Focus**: Seeking immune disease partners while advancing oncology pipeline independently.


**【CFO Financial Commentary】**
- Q3 2023 R&D expenses: $4 million (down $6.4 million YoY due to reduced mupadolimab costs).
- Net loss: $6 million (including $0.9 million non-cash loss from Angel Pharmaceuticals).
- Cash position: $32.2 million as of Q3 2023; projected $27-28 million runway into late 2024.

**【CEO Business Update】**
- **Phase III PTCL Trial**: Finalized protocol submitted to FDA; 150-patient trial to compare soquelitinib vs standard chemotherapy. Expected initiation Q2 2024 with U.S.-focused sites.
- **Immune Disease Potential**: Preclinical data shows ITK inhibition blocks Th2/Th17 cytokines (IL-4, IL-5, IL-17) in models of asthma, psoriasis, pulmonary fibrosis.
- **Partnership Strategy**: Seeking pharma/biotech partners for immune disease programs; oncology focus continues with soquelitinib.

**【James Rosenbaum - Immune Disease Update】**
- ITK inhibition mechanism: Blocks inflammatory cytokine production upstream of existing biologics; spares Th1 cells critical for infection response.
- Preclinical validation: Erasmus University study confirms ITK inhibition enhances anti-tumor immunity in solid tumors.

**【Q&A Highlights】**
- **ASH 2023 Data**: Updated soquelitinib PTCL responses (43% ORR, 86% DCR) with durability >21 months; single-cell RNA seq analysis of Th1/Th2/Th17 balance.
- **RCC Trial Thresholds**: Monotherapy ORR >10% in checkpoint-refractory RCC would be significant; combination trials planned.
- **Funding Strategy**: Phase III trial costs to be managed via partnerships and existing cash runway; no immediate capital raise needed.


Actual									-0.44	-0.36	-0.33	0.92	-0.34	-0.28	-0.24	-0.2	-0.18	-0.18	-0.32	-0.21	-0.17	-0.14	-0.12	-0.14	-0.12	-0.07	-0.6	-0.18	-0.13	-0.1	-0.12	-0.15
Forecast									-0.398	-0.276	-0.24	-0.3225	-0.31	-0.3125	-0.2375	-0.1875	-0.1533	-0.1767	-0.1567	-0.2067	-0.1567	-0.14	-0.1225	-0.12	-0.135	-0.115	-0.11	-0.1167	-0.12	-0.1333	-0.1269	-0.1294
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-10.55%	-30.43%	-37.50%	+385.27%	-9.68%	+10.40%	-1.05%	-6.67%	-17.42%	-1.87%	-104.21%	-1.60%	-8.49%	0.00%	+2.04%	-16.67%	+11.11%	+39.13%	-445.45%	-54.24%	-8.33%	+24.98%	+5.44%	-15.92%

Actual	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

CRVS

CRVS fundamentals

CRVS Q4 2025 Earnings

Earnings Call

You can ask Aime

CRVS

CRVS fundamentals

CRVS Q4 2025 Earnings

Earnings Call

CRVS Earnings Call Summary for Q4/20254:30 PM on Mar 12, 2026

CRVS Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

CRVS Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

CRVS Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

CRVS Earnings Call Summary for Q4/20244:30 PM on Mar 25, 2025

You can ask Aime